Clinical Evidence Takes Center Stage at TomoTherapy Americas User Education Symposium
22 Abril 2011 - 7:00AM
Marketwired
Emerging clinical evidence was highlighted at the Americas User
Education Symposium hosted by TomoTherapy Incorporated (NASDAQ:
TOMO) last month in Charleston, S.C. With more than 80 TomoTherapy
customers in attendance, the meeting featured presentations from
clinicians who submitted abstracts on how TomoTherapy® radiation
therapy technology is being effectively used for the treatment of
numerous types of cancers. The meeting also explored
TomoTherapy-related clinical and dosimetric trials, and how the
system can be used to deliver stereotactic body radiation therapy
(SBRT).
A key element of the TomoTherapy Americas User Education
Symposium was a presentation by Minesh Mehta, M.D., professor of
Radiation Oncology, Feinberg School of Medicine, Northwestern
University, Chicago. The presentation provided an overview of
TomoTherapy treatment-related studies that included tumors of the
brain, head and neck, breast, lung, pelvis, as well as treatment of
multiple body metastases.
An important aspect of the presentation was increasing evidence
that TomoTherapy technology is well-suited for image-guided SBRT,
which could serve as an effective treatment option for patients
with early-stage lung cancer who are considered inoperable because
of complications, such as poor cardiopulmonary function.
"TomoTherapy is ideally-suited for an image-guided stereotactic
radiotherapy approach. It enables us to target the early-stage
cancerous lesions of the lung without damaging healthy lung tissue,
and allows us both excellent outcomes and good control rates,"
concluded Dr. Mehta.
Benjamin Sintay, Ph.D., lead clinical physicist, Moses Cone
Regional Cancer Center, Greensboro, N.C., also addressed the topic
of SBRT, reporting on his center's successful use of the
TomoTherapy system to deliver SBRT for 18 percent of their
patients, including those presenting with lung, liver, paraspinal
and bone cancers. In another study, Paul Read, M.D., Ph.D.,
University of Virginia, Charlottesville, Va., presented his
center's use of the TomoTherapy system to deliver highly-precise,
SBRT-like dose distributions for hypofractionated palliative care
of patients, which resulted in "more rapid and patient-convenient
palliation with less toxicity."
"The program at our Americas User Education Symposium clearly
illustrates the broad clinical application of our technology," said
Stephanie Key, TomoTherapy's director of clinical marketing. "It is
great to be able to provide a forum for sharing experiences in the
use of the TomoTherapy system."
About TomoTherapy Incorporated TomoTherapy
Incorporated develops, markets and sells advanced radiation therapy
solutions that can be used to treat a wide variety of cancers, from
the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments
with speed and precision while reducing radiation exposure to
surrounding healthy tissue. TomoTherapy's suite of solutions
include its Hi-Art® treatment system, which has been used to
deliver more than three million CT-guided, helical
intensity-modulated radiation therapy (IMRT) treatment fractions;
the TomoHD™ treatment system, designed to enable cancer centers to
treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to
improve access and availability of state-of-the-art cancer care.
TomoTherapy's stock is traded on the NASDAQ Global Select Market
under the symbol TOMO. To learn more about TomoTherapy, please
visit TomoTherapy.com.
©2011 TomoTherapy Incorporated. All rights reserved.
TomoTherapy, Tomo, TomoHD, TomoMobile, TomoDirect, TQA, the
TomoTherapy logo and Hi-Art are among trademarks, service marks or
registered trademarks of TomoTherapy Incorporated in the United
States and other countries.
Investor Contact: Thomas E. Powell Chief Financial
Officer 608.824.2800 Email Contact Media Contacts: Kevin
O'Malley Director, Corporate Communications 608.824.3384 Email
Contact Susan Lehman Rockpoint Public Relations 510.832.6006 Email
Contact
Tom Online (NASDAQ:TOMO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Tom Online (NASDAQ:TOMO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024